Intercept Pharmaceuticals Stock News

Intercept Pharmaceuticals (NASDAQ:ICPT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 2 0

Raymond James has decided to maintain its Outperform rating of Intercept Pharmaceuticals (NASDAQ:ICPT) and raise its price target from $26.00 to $28.00. Shares of Intercept Pharmaceuticals are trading

GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 145% to $38.45 on continued volatility following the company's IPO on Thursday. Axsome Therapeutics, Inc. (NASDAQ: AXSM) gained 41% to $59.84 af

MORRISTOWN, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of

Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.

Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.

Intercept (ICPT) posts a wider Q2 loss while sales beat estimates. The company reissues guidance.

Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and +5.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and +5.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Intercept (ICPT) posts a wider Q2 loss while sales beat estimates. The company reissues guidance.

Within the last quarter, Intercept Pharmaceuticals (NASDAQ:ICPT) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 2

Intercept (ICPT) posts a wider Q2 loss and sales miss estimates. The company reissues guidance.

Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and 24.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT ) Q2 2022 Results Conference Call August 2, 2022 8:30 AM ET Company Participants Nareg Sagherian - ED, IR Jerry Durso - President and CEO Linda Richardson

Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and 24.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?